Selective inhibition of BCL-2 is a promising target in patients with high-risk myelodysplastic syndromes and adverse mutational profile

Somatic mutations in genes such as ASXL1, RUNX1, TP53 or EZH2 adversely affect the outcome of patients with myelodysplastic syndromes (MDS). Since selective BCL-2 inhibition is a promising treatment strategy in hematologic malignancies, we tested the therapeutic impact of ABT-199 on MDS patient samp...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Oncotarget
Main Authors: Reidel, Veronika, Kauschinger, Johanna, Hauch, Richard T., Müller-Thomas, Catharina, Nadarajah, Niroshan, Burgkart, Rainer, Schmidt, Burkhard, Hempel, Dirk, Jacob, Anne, Slotta-Huspenina, Julia, Höckendorf, Ulrike, Peschel, Christian, Kern, Wolfgang, Haferlach, Torsten, Götze, Katharina S., Jilg, Stefanie, Jost, Philipp J.
Formato: Artigo
Idioma:Inglês
Publicado: Impact Journals LLC 2018
Assuntos:
Research Paper: Autophagy and Cell Death
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5915115/
https://ncbi.nlm.nih.gov/pubmed/29707107
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.24775
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares